<p>Oppenheimer  Co. Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 Hims  Hers Health, Inc. (NYSE:HIMS - 免費報告) 的持倉減少了 83.8%。該機構投資者在此期間出售了 37,448 股後，持有該公司 7,254 股股票。Oppenheimer  Co. Inc. 在 Hims  Hers Health 的持股在最近一個季度末價值 236,000 美元。</p>
<p>獲取 <strong>Hims  Hers Health</strong> 警報：</p>
<ul>
<li>Hims  Hers 財報前瞻：諾和諾德的轉變將 GLP-1 策略置於焦點</li>
</ul>
<p>其他對沖基金最近也對該公司的持倉進行了調整。Pathway Capital Management LP 在第三季度購買了 Hims  Hers Health 的新股份，價值約 6,766,000 美元。Steadview Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持倉提高了 80.0%。Steadview Capital Management LLC 目前持有該公司 701,845 股股票，價值 39,809,000 美元，此前在上個季度又購買了 311,845 股。Farallon Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持倉提高了 30.8%。Farallon Capital Management LLC 目前持有該公司 10,746,852 股股票，價值 609,561,000 美元，此前在上個季度又購買了 2,533,271 股。BIT Capital GmbH 在第三季度將其在 Hims  Hers Health 的持倉提高了 73.8%。BIT Capital GmbH 目前持有該公司 2,210,384 股股票，價值 125,373,000 美元，此前在上個季度又購買了 938,728 股。最後，密歇根州退休系統在第三季度將其在 Hims  Hers Health 的持倉提高了 49.2%。密歇根州退休系統目前持有該公司 2,057,700 股股票，價值 116,713,000 美元，此前在上個季度又購買了 678,600 股。63.52% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>Hims  Hers Health 股票上漲 0.7%</h2>
<p>NYSE:HIMS 的股票週一開盤價為 28.46 美元。該公司的流動比率為 1.90，速動比率為 1.70，債務與股本比率為 1.80。Hims  Hers Health, Inc. 的 12 個月最低價為 13.74 美元，最高價為 70.43 美元。該公司的 50 日移動平均價格為 22.56 美元，200 日移動平均價格為 29.75 美元。該公司的市值為 64.9 億美元，市盈率為 55.81，PEG 比率為 3.85，貝塔值為 2.43。</p>
<ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
<p>Hims  Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 2 月 23 日星期一公佈了季度財報。該公司報告本季度每股收益為 0.08 美元，超出分析師共識預期的 0.02 美元，超出幅度為 0.06 美元。Hims  Hers Health 的淨利潤率為 5.47%，股本回報率為 22.48%。該公司本季度的收入為 6.1782 億美元，而共識預期為 6.1948 億美元。去年同期，該公司每股收益為 0.11 美元。該公司本季度的收入較去年同期增長了 28.4%。整體來看，股票研究分析師預測 Hims  Hers Health, Inc. 本年度每股收益將達到 0.53 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>HIMS 一直是多份研究分析師報告的主題。Leerink Partners 在 3 月 16 日的研究報告中將 Hims  Hers Health 的目標價從 17.50 美元上調至 25.00 美元，並給予該股票 &#34;市場表現&#34; 的評級。Needham  Company LLC 在 3 月 9 日的報告中將 Hims  Hers Health 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;，並設定了 30.00 美元的目標價。TD Cowen 在 3 月 27 日的報告中將 Hims  Hers Health 的目標價從 25.00 美元下調至 23.00 美元，並對該公司給予了 &#34;持有&#34; 的評級。Truist Financial 在 2 月 24 日的報告中重申了 &#34;持有&#34; 的評級，並對 Hims  Hers Health 的股票設定了 18.00 美元的目標價（低於 37.00 美元）。最後，巴克萊在 3 月 11 日的報告中將 Hims  Hers Health 的目標價從 25.00 美元上調至 29.00 美元，並給予該公司 &#34;超配&#34; 的評級。四位分析師對該股票給予了買入評級，十二位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Hims  Hers Health 目前的共識評級為 &#34;持有&#34;，平均目標價為 31.86 美元。</p>
<ul>
<li>亞馬遜對 Hims 的影響：其 GLP-1 進入意味着什麼</li>
</ul>
<p><strong>獲取我們最新的 HIMS 股票報告</strong></p>
<h2>內部活動</h2>
<p>在其他 Hims  Hers Health 的新聞中，內部人士 Irene Becklund 於 3 月 17 日星期二出售了 5,529 股該公司的股票。股票以平均價格 24.69 美元出售，總價值為 136,511.01 美元。出售完成後，內部人士持有該公司 8,752 股股票，價值 216,086.88 美元。此交易代表其持股減少了 38.72%。該出售在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，內部人士 Soleil Boughton 於 4 月 20 日星期一出售了 9,463 股該公司的股票。股票以平均價格 30.00 美元出售，總交易額為 283,890.00 美元。出售完成後，內部人士直接持有該公司 299,368 股股票，價值約 8,981,040 美元。該交易的持倉減少了 3.06%。有關此出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去九十天內出售了價值 5,285,706 美元的 204,857 股公司股票。11.76% 的股票目前由公司內部人士持有。</p>
<h2>Hims  Hers Health 概況</h2>
<p>(免費報告)</p>
<p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，在美國提供直接面向消費者的個人護理產品和虛擬醫療服務。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合的數字體驗，將用户與持牌醫療提供者連接起來，使其能夠進行在線諮詢和開處方，涵蓋多種健康狀況。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
<p>公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 Hims &amp; Hers Health</li>
<li>超越 NVIDIA：強勁勢頭的 Picks-and-Shovels AI 投資</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療股票將從這項重大法案中受益</li>
</ul>
<p><strong>想看看其他對 HIMS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

2 倍做多 HIMS ETF - Defiance

HIMY

<p>Oppenheimer & Co. Inc. 已顯著減少在 Hims & Hers Health, Inc. 的持股，減少幅度達到 83.8%，目前持有 7,254 股，此前在第四季度出售了 37,448 股。其他對沖基金也調整了他們的持倉，其中 Pathway Capital Management 和 Steadview Capital Management 的增持尤為顯著。Hims & Hers Health 的股票開盤價為 28.46 美元，市值為 64.9 億美元，最近的每股收益為 0.08 美元，超出預期。分析師的評級意見不一，目標價格範圍在 18.00 美元到 30.00 美元之間</p>

<p>Oppenheimer &amp; Co. Inc. reduced its position in Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) by 83.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,254 shares of the company's stock after selling 37,448 shares during the period. Oppenheimer &amp; Co. Inc.'s holdings in Hims &amp; Hers Health were worth $236,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Oppenheimer  Co. Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 Hims  Hers Health, Inc. (NYSE:HIMS - 免費報告) 的持倉減少了 83.8%。該機構投資者在此期間出售了 37,448 股後，持有該公司 7,254 股股票。Oppenheimer  Co. Inc. 在 Hims  Hers Health 的持股在最近一個季度末價值 236,000 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims  Hers Health</strong> 警報：</p>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 財報前瞻：諾和諾德的轉變將 GLP-1 策略置於焦點</li>
</ul>
</div><p>Other hedge funds also recently made changes to their positions in the company. Pathway Capital Management LP purchased a new stake in shares of Hims &amp; Hers Health in the third quarter worth about $6,766,000. Steadview Capital Management LLC lifted its position in shares of Hims &amp; Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after buying an additional 311,845 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock worth $609,561,000 after buying an additional 2,533,271 shares in the last quarter. BIT Capital GmbH lifted its position in shares of Hims &amp; Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock worth $125,373,000 after buying an additional 938,728 shares in the last quarter. Finally, State of Michigan Retirement System lifted its position in shares of Hims &amp; Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock worth $116,713,000 after buying an additional 678,600 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金最近也對該公司的持倉進行了調整。Pathway Capital Management LP 在第三季度購買了 Hims  Hers Health 的新股份，價值約 6,766,000 美元。Steadview Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持倉提高了 80.0%。Steadview Capital Management LLC 目前持有該公司 701,845 股股票，價值 39,809,000 美元，此前在上個季度又購買了 311,845 股。Farallon Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持倉提高了 30.8%。Farallon Capital Management LLC 目前持有該公司 10,746,852 股股票，價值 609,561,000 美元，此前在上個季度又購買了 2,533,271 股。BIT Capital GmbH 在第三季度將其在 Hims  Hers Health 的持倉提高了 73.8%。BIT Capital GmbH 目前持有該公司 2,210,384 股股票，價值 125,373,000 美元，此前在上個季度又購買了 938,728 股。最後，密歇根州退休系統在第三季度將其在 Hims  Hers Health 的持倉提高了 49.2%。密歇根州退休系統目前持有該公司 2,057,700 股股票，價值 116,713,000 美元，此前在上個季度又購買了 678,600 股。63.52% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>Hims &amp; Hers Health Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Hims  Hers Health 股票上漲 0.7%</h2>
</div><p>Shares of NYSE:HIMS opened at $28.46 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims &amp; Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a 50-day moving average price of $22.56 and a 200 day moving average price of $29.75. The company has a market cap of $6.49 billion, a price-to-earnings ratio of 55.81, a PEG ratio of 3.85 and a beta of 2.43.</p>
<div class="lb-trans"><p>NYSE:HIMS 的股票週一開盤價為 28.46 美元。該公司的流動比率為 1.90，速動比率為 1.70，債務與股本比率為 1.80。Hims  Hers Health, Inc. 的 12 個月最低價為 13.74 美元，最高價為 70.43 美元。該公司的 50 日移動平均價格為 22.56 美元，200 日移動平均價格為 29.75 美元。該公司的市值為 64.9 億美元，市盈率為 55.81，PEG 比率為 3.85，貝塔值為 2.43。</p>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. Hims &amp; Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter last year, the firm earned $0.11 EPS. The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. As a group, equities research analysts predict that Hims &amp; Hers Health, Inc. will post 0.53 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 2 月 23 日星期一公佈了季度財報。該公司報告本季度每股收益為 0.08 美元，超出分析師共識預期的 0.02 美元，超出幅度為 0.06 美元。Hims  Hers Health 的淨利潤率為 5.47%，股本回報率為 22.48%。該公司本季度的收入為 6.1782 億美元，而共識預期為 6.1948 億美元。去年同期，該公司每股收益為 0.11 美元。該公司本季度的收入較去年同期增長了 28.4%。整體來看，股票研究分析師預測 Hims  Hers Health, Inc. 本年度每股收益將達到 0.53 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>HIMS has been the topic of a number of research analyst reports. Leerink Partners boosted their target price on Hims &amp; Hers Health from $17.50 to $25.00 and gave the stock a &#34;market perform&#34; rating in a research report on Monday, March 16th. Needham &amp; Company LLC raised shares of Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $30.00 price target for the company in a report on Monday, March 9th. TD Cowen lowered their price target on shares of Hims &amp; Hers Health from $25.00 to $23.00 and set a &#34;hold&#34; rating for the company in a report on Friday, March 27th. Truist Financial reaffirmed a &#34;hold&#34; rating and issued a $18.00 price target (down from $37.00) on shares of Hims &amp; Hers Health in a report on Tuesday, February 24th. Finally, Barclays increased their price target on shares of Hims &amp; Hers Health from $25.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 11th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hims &amp; Hers Health currently has a consensus rating of &#34;Hold&#34; and an average target price of $31.86.</p>
<div class="lb-trans"><p>HIMS 一直是多份研究分析師報告的主題。Leerink Partners 在 3 月 16 日的研究報告中將 Hims  Hers Health 的目標價從 17.50 美元上調至 25.00 美元，並給予該股票 &#34;市場表現&#34; 的評級。Needham  Company LLC 在 3 月 9 日的報告中將 Hims  Hers Health 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;，並設定了 30.00 美元的目標價。TD Cowen 在 3 月 27 日的報告中將 Hims  Hers Health 的目標價從 25.00 美元下調至 23.00 美元，並對該公司給予了 &#34;持有&#34; 的評級。Truist Financial 在 2 月 24 日的報告中重申了 &#34;持有&#34; 的評級，並對 Hims  Hers Health 的股票設定了 18.00 美元的目標價（低於 37.00 美元）。最後，巴克萊在 3 月 11 日的報告中將 Hims  Hers Health 的目標價從 25.00 美元上調至 29.00 美元，並給予該公司 &#34;超配&#34; 的評級。四位分析師對該股票給予了買入評級，十二位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Hims  Hers Health 目前的共識評級為 &#34;持有&#34;，平均目標價為 31.86 美元。</p>
</div><ul>
<li>Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means</li>
</ul>
<div class="lb-trans"><ul>
<li>亞馬遜對 Hims 的影響：其 GLP-1 進入意味着什麼</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on HIMS</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 HIMS 股票報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Hims &amp; Hers Health news, insider Irene Becklund sold 5,529 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares of the company's stock, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 9,463 shares of the firm's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company's stock, valued at approximately $8,981,040. The trade was a 3.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 204,857 shares of company stock worth $5,285,706 in the last ninety days. 11.76% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Hims  Hers Health 的新聞中，內部人士 Irene Becklund 於 3 月 17 日星期二出售了 5,529 股該公司的股票。股票以平均價格 24.69 美元出售，總價值為 136,511.01 美元。出售完成後，內部人士持有該公司 8,752 股股票，價值 216,086.88 美元。此交易代表其持股減少了 38.72%。該出售在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，內部人士 Soleil Boughton 於 4 月 20 日星期一出售了 9,463 股該公司的股票。股票以平均價格 30.00 美元出售，總交易額為 283,890.00 美元。出售完成後，內部人士直接持有該公司 299,368 股股票，價值約 8,981,040 美元。該交易的持倉減少了 3.06%。有關此出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去九十天內出售了價值 5,285,706 美元的 204,857 股公司股票。11.76% 的股票目前由公司內部人士持有。</p>
</div><h2>Hims &amp; Hers Health Profile</h2>
<div class="lb-trans"><h2>Hims  Hers Health 概況</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，在美國提供直接面向消費者的個人護理產品和虛擬醫療服務。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合的數字體驗，將用户與持牌醫療提供者連接起來，使其能夠進行在線諮詢和開處方，涵蓋多種健康狀況。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Hims &amp; Hers Health</li>
<li>超越 NVIDIA：強勁勢頭的 Picks-and-Shovels AI 投資</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療股票將從這項重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HIMS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 HIMS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Oppenheimer & Co. Inc. Cuts Holdings in Hims & Hers Health, Inc. $HIMS

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

奧本海默控股

諾和諾德公司

禮來

Truist Financial

巴克萊銀行

亞馬遜

Oppenheimer & Co. Inc. 減持了 Hims & Hers Health, Inc. 的持股 $HIMS